Pulmatrix And Cullgen Announce Proposed Merger; Pre-Merger Pulmatrix Stockholers To Own ~3.6% Of Combined Company; Pre-Merger Cullgen Stockholders To Own ~96.4% Of Combined Company Under Name Cullgen
Benzinga Newsdesk 1 year ago
M&ANews
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with
three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and
one for the treatment of acute and chronic pain
Combined company expected to have approximately $65 million of cash and cash equivalents at close to
provide funding through multiple clinical milestones and expected runway through 2026
As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate,
PUR3100, and other development candidates based on its iSPERSE™ technology
Cullgen and Pulmatrix will host an informational webcast about the proposed merger that will be made